{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:53Z","timestamp":1772166173927,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ganzhou Cancer Hospital Science and Technology Plan Project","award":["GZKJB2010103"],"award-info":[{"award-number":["GZKJB2010103"]}]},{"DOI":"10.13039\/501100013064","name":"Key Research and Development Program of Jiangxi Province","doi-asserted-by":"crossref","award":["Ganzhou Caijiaozi [2017] No. 8"],"award-info":[{"award-number":["Ganzhou Caijiaozi [2017] No. 8"]}],"id":[{"id":"10.13039\/501100013064","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the clinical outcomes for patients with stage IB2\/IIA2 cervical squamous cell carcinoma treated with neoadjuvant chemotherapy combined with radical surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 68 patients with cervical squamous cell carcinoma were randomly divided into the experimental group (\n                      <jats:italic>n<\/jats:italic>\n                      = 35) and the control group (\n                      <jats:italic>n<\/jats:italic>\n                      = 33). The patients in the experimental group received paclitaxel plus cisplatin neoadjuvant chemotherapy for two cycles, then underwent radical hysterectomy and bilateral adnexectomy at 2\u2009weeks post-chemotherapy. The control group only underwent radical hysterectomy and bilateral adnexectomy after the diagnosis of cervical squamous cell carcinoma. The toxic and side effects of chemotherapy in the experimental group were observed. Also, the operation method, operation time, blood loss, grade of wound healing, complications, and postoperative pathology were noted in the two groups. Primary foci and pelvic lymph node recurrence and distant metastasis were observed, and 3-year and 5-year survival rates were calculated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Only one patient in the experiment had grade III bone marrow suppression; no other grade III and IV chemotherapy toxic reactions were observed. The operation was successfully completed in all patients. The operation time, intraoperative blood loss, placement of the ureteral catheter, bladder injury, ureteric injury, postoperative urinary tub, pelvic drainage tube indwelling time, anal exhaust time, postoperative complications, and metastatic ratio of lymph nodes were not significantly different between the two groups (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05). The number of dissected lymph nodes, deep myometrial invasion, and vascular tumor emboli showed a significant difference in the experimental group compared with the control group (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). The 3-year disease-free survival (82.9% vs 81.9%), 5-year disease-free survival (71.4% vs 60.6%), 3-year overall survival (91.4% vs 87.8%), and 5-year overall survival (82.9% vs 75.6%) were not statistically significantly different between the experimental group and the control group (\n                      <jats:italic>P<\/jats:italic>\n                      &gt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy in IB2\/IIA2 stage cervical squamous cell carcinoma showed low toxic side effects. Radical surgery after chemotherapy is safe and feasible. It plays a coordinating role in reducing the tumor infiltration depth of the deep muscle layer and the incidence of vascular tumor emboli, reducing the use of postoperative adjuvant therapy, and improving the quality of life of patients, but does not improve the 3-year\/5-year survival rate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-021-02318-y","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T10:02:47Z","timestamp":1626084167000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neoadjuvant chemotherapy combined with radical surgery for stage IB2\/IIA2 cervical squamous cell carcinoma: a prospective, randomized controlled study of 35 patients"],"prefix":"10.1186","volume":"19","author":[{"given":"Huang","family":"Jing","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Xiuhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liao","family":"Zhenrong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Xiyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo","family":"Deping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shen","family":"Changmei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Yiyun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"2318_CR1","volume":"5","author":"A Marc","year":"2018","unstructured":"Marc A, Xu L, Cindy S, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2318_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/GCO.0000000000000241","volume":"28","author":"S Pimple","year":"2016","unstructured":"Pimple S, Mishra G, Shastri S. Global strategies for cervical cancer prevention. Curr Opin Obstet Gynecol. 2016;28(1):4\u201310.","journal-title":"Curr Opin Obstet Gynecol."},{"issue":"2","key":"2318_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","volume":"105","author":"FIGO committee on gynecology oncology","year":"2009","unstructured":"FIGO committee on gynecology oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynecol Obstet. 2009;105(2):103\u201311.","journal-title":"Int J Gynecol Obstet"},{"issue":"2","key":"2318_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.radonc.2017.04.005","volume":"123","author":"P de Boer","year":"2017","unstructured":"de Boer P, J\u00fcrgenliemk-Schulz IM, Westerveld H, de Leeuw AAC, D\u00e1vila-Fajardo R, Rasch CRN, et al. Patterns of care survey: radiotherapy for women with locally advanced cervical cancer. Radiother Oncol. 2017;123(2):306\u201311.","journal-title":"Radiother Oncol."},{"issue":"10","key":"2318_CR5","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/bjc.2013.179","volume":"108","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013;108(10):1957\u201363.","journal-title":"Br J Cancer."},{"issue":"1","key":"2318_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12957-020-01905-9","volume":"18","author":"T Hua","year":"2020","unstructured":"Hua T, Wan T, Zhang X, Haifeng G, Feng Y, He H, et al. Potential risks in sentinel lymph node biopsy for cervical cancer: a single-institution pilot study. World J Surg Oncol. 2020;18(1):133.","journal-title":"World J Surg Oncol."},{"issue":"1","key":"2318_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/ijgc-2019-000647","volume":"30","author":"FM Tesfai","year":"2020","unstructured":"Tesfai FM, Kroep JR, Gaarenstroom K, De Kroon C. Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and Obstetrics 2009 stage IB1-IIA) after neoadjuvant chemotherapy. Int J Gynecol Cancer. 2020;30(1):115\u201321.","journal-title":"Int J Gynecol Cancer."},{"issue":"11","key":"2318_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225264","volume":"14","author":"W Zou","year":"2019","unstructured":"Zou W, Han Y, Yang Z, Hu C, Feng Y, Zhang H, et al. Neoadjuvant chemotherapy plus surgery versus concurrent chemoradiotherapy in stage IB2-IIB cervical cancer: a systematic review and meta-analysis. PLoS One. 2019;14(11):e0225264.","journal-title":"PLoS One."},{"issue":"1","key":"2318_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/s41598-018-19948-0","volume":"8","author":"S-Y Kong","year":"2018","unstructured":"Kong S-Y, Huang K, Zeng C, Ma X, Wang S. The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis. Sci Rep. 2018;8(1):1545.","journal-title":"Sci Rep."},{"key":"2318_CR10","doi-asserted-by":"publisher","first-page":"101945","DOI":"10.1016\/j.ctrv.2019.101945","volume":"83","author":"C Marchetti","year":"2020","unstructured":"Marchetti C, Fagotti A, Tombolini V, Scambia G, De Felice F. Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;83:101945.","journal-title":"Cancer Treat Rev."},{"issue":"10","key":"2318_CR11","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1586\/14737140.2015.1079777","volume":"15","author":"M Lapresa","year":"2015","unstructured":"Lapresa M, Parma G, Portuesi R, Colombo N. Neoadjuvant chemotherapy in cervical cancer: an update. Expert Rev Anticancer Ther. 2015;15(10):1171\u201381.","journal-title":"Expert Rev Anticancer Ther."},{"issue":"4","key":"2318_CR12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/IGC.0000000000000663","volume":"26","author":"CRAS de Azevedo","year":"2016","unstructured":"de Azevedo CRAS, Thuler LCS, de Mello MJG, Ferreira CG. Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma: a review. Int J Gynecol Cancer. 2016;26(4):729\u201336.","journal-title":"Int J Gynecol Cancer."},{"issue":"6","key":"2318_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/jso.22136","volume":"105","author":"M Hosaka","year":"2012","unstructured":"Hosaka M, Watari H, Kato T, Odagiri T, Konno Y, Endo D, et al. Clinical efficacy of paclitaxel\/cisplatin as an adjuvant chemotherapy for patients with cervical cancer who underwent radical hysterectomy and systematic lymphadenectomy. J Surg Oncol. 2012;105(6):612\u20136.","journal-title":"J Surg Oncol."},{"issue":"5","key":"2318_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1136\/ijgc-2019-000398","volume":"29","author":"M Plante","year":"2019","unstructured":"Plante M, van Trommel N, Lheureux S, Oza AM, Wang L, Sikorska K, et al. FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG\/CCRN and multicenter study. Int J Gynecol Cancer. 2019;29(5):969\u201375.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"2318_CR15","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/jog.13885","volume":"45","author":"T Mori","year":"2019","unstructured":"Mori T, Makino H, Okubo T, Fujiwara Y, Sawada M, Kuroboshi H, et al. Multi-institutional phase II study of neoadjuvant irinotecan and nedaplatin followed by radical hysterectomy and the adjuvant chemotherapy for locally advanced, bulky uterine cervical cancer: a Kansai Clinical Oncology Group study (KCOG-G1201). J Obstet Gynaecol Res. 2019;45(3):671\u20138.","journal-title":"J Obstet Gynaecol Res."},{"issue":"1","key":"2318_CR16","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12957-020-01997-3","volume":"18","author":"A Lewandowska","year":"2020","unstructured":"Lewandowska A, Szubert S, Koper K, Koper A, Cwynar G, Wicherek L. Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer. World J Surg Onc. 2020;18(1):234.","journal-title":"World J Surg Onc."},{"issue":"1","key":"2318_CR17","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ygyno.2009.09.040","volume":"116","author":"LT Gien","year":"2010","unstructured":"Gien LT, Beauchemin M-C, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol. 2010;116(1):140\u20136.","journal-title":"Gynecol Oncol."},{"issue":"2","key":"2318_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ijrobp.2011.12.013","volume":"84","author":"Y-T Huang","year":"2012","unstructured":"Huang Y-T, Wang C-C, Tsai C-S, Lai C-H, Chang T-C, Chou H-H, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(2):420\u20137.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2318_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/AOG.0000000000003311","volume":"134","author":"D Wright Jason","year":"2019","unstructured":"Wright Jason D, Koji M, Yongmei H, et al. Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics cervical cancer staging guidelines. Obstet Gynecol. 2019;134:49\u201357.","journal-title":"Obstet Gynecol"},{"issue":"12","key":"2318_CR20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00066-017-1174-1","volume":"193","author":"P Hass","year":"2017","unstructured":"Hass P, Eggemann H, Costa SD, Ignatov A. Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer. Strahlenther Onkol. 2017;193(12):1048\u201355.","journal-title":"Strahlenther Onkol."},{"issue":"10","key":"2318_CR21","doi-asserted-by":"publisher","first-page":"9299","DOI":"10.18632\/oncotarget.24271","volume":"9","author":"R Sun","year":"2018","unstructured":"Sun R, Koubaa I, Limkin EJ, Dumas I, Bentivegna E, Castanon E, et al. Locally advanced cervical cancer with bladder invasion: clinical outcomes and predictive factors for vesicovaginal fistulae. Oncotarget Actions. 2018;9(10):9299\u2013310.","journal-title":"Oncotarget Actions."},{"key":"2318_CR22","doi-asserted-by":"crossref","unstructured":"Sudeep Gupta, Amita Maheshwari, Pallavi Parab, Umesh Mahantshetty, Rohini Hawaldar, Supriya Sastri Chopra, Rajendra Kerkar, Reena Engineer, Hemant Tongaonkar, Jaya Ghosh, Seema Gulia, Neha Kumar, T Surappa Shylasree, Renuka Gawade, Yogesh Kembhavi, Madhuri Gaikar, Santosh Menon, Meenakshi Thakur, Shyam Shrivastava, Rajendra Badwe. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548-1555.","DOI":"10.1200\/JCO.2017.75.9985"},{"issue":"10","key":"2318_CR23","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/bjc.2013.179","volume":"108","author":"N Katsumata","year":"2013","unstructured":"Katsumata N, Yoshikawa H, Kobayashi H, Saito T, Kuzuya K, Nakanishi T, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013 May 28;108(10):1957\u201363.","journal-title":"Br J Cancer."},{"issue":"39","key":"2318_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017234","volume":"98","author":"W Yan","year":"2019","unstructured":"Yan W, Si L, Ding Y, Qiu S, Zhang Q, Liu L. Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: a retrospective cohort study in China. Medicine (Baltimore). 2019;98(39):e17234.","journal-title":"Medicine (Baltimore)."},{"issue":"1","key":"2318_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ygyno.2014.01.042","volume":"133","author":"D Lorusso","year":"2014","unstructured":"Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 2014 Apr;133(1):117\u201323.","journal-title":"Gynecol Oncol."},{"key":"2318_CR26","doi-asserted-by":"crossref","unstructured":"Hui Zhao, Yue He, Li-Rong Zhu, Jian-Liu Wang, Hong-Yan Guo, Ting Xu, Yi-Qin Wang, Ying Yao, Yu-Mei Wu. Effect of neoadjuvant chemotherapy followed by radical surgery for FIGO stage IB2\/IIA2 cervical cancer: a multi-center retrospective clinical study. Medicine (Baltimore). 2019;98(21):e15604.","DOI":"10.1097\/MD.0000000000015604"},{"issue":"9","key":"2318_CR27","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.21873\/anticanres.14485","volume":"40","author":"A Gadducci","year":"2020","unstructured":"Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020;40(9):4819\u201328.","journal-title":"Anticancer Res."},{"key":"2318_CR28","doi-asserted-by":"crossref","unstructured":"Tian Tian,Gong Xing,Gao Xudong et al. Comparison of survival outcomes of locally advanced cervical cancer by histopathological types in the surveillance, epidemiology, and end results (SEER) database: a propensity score matching study. Infect Agent Cancer, 2020, 15: 33.","DOI":"10.1186\/s13027-020-00299-3"},{"key":"2318_CR29","doi-asserted-by":"crossref","unstructured":"Caryn Wujanto, Bok Ai Choo, David Tan, Arunachalam Ilancheran, Joseph Ng, Jeffrey J H Low, Liang Shen, Johann Tang, Vicky Koh. Does external beam radiation boost to pelvic lymph nodes improve outcomes in patients with locally advanced cervical cancer? BMC Cancer. 2019;19(1):385.","DOI":"10.1186\/s12885-019-5594-4"},{"issue":"2","key":"2318_CR30","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","volume":"8","author":"M Arbyn","year":"2020","unstructured":"Arbyn M, Weiderpass E, Bruni L, de Sanjos\u00e9 S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191\u2013203.","journal-title":"Lancet Glob Health."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-021-02318-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-021-02318-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T10:03:14Z","timestamp":1626084194000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-021-02318-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2318"],"URL":"https:\/\/doi.org\/10.1186\/s12957-021-02318-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-273621\/v1","asserted-by":"object"}]},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"assertion":[{"value":"23 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study received the Ganzhou Cancer Hospital Ethical Committee approval (2018A152).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}